

AHCL/ SE/ 16 /2022-23

August 12, 2022

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting- Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)

Pursuant to the subject regulation(s), we wish to inform that the Board of Directors of the Company at its meeting held today (August 12, 2022) had inter-alia approved the

1. The Unaudited Financial Results for the quarter ended June 30, 2022 as recommended by the Audit Committee at its meeting held today (August 12, 2022). The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company, is enclosed.
2. Approved appointment of Ms. Meenalochani Raghunathan (DIN: 07145001) as an Additional Director (Non-Executive Independent) on the Board of the Company with effect from 12.08.2022

The Board Meeting commenced at 12.30 P.M. (IST) and concluded at 05.45 P.M. (IST).

Request you to take the above on record and acknowledge.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited


(M Srinivasan)
Company Secretary & Compliance Officer



Encl:

1. Un-audited Standalone Financials Results for the quarter ended June 30, 2022
2. Limited Review Report

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel : +91-44 - 2499 4465
+91-44 - 2466 9000
Fax : +91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

Statement of unaudited Financial Results for the quarter ended 30 June 2022

		--- (Rs.in Lakhs)			
	Particulars	Quarter ended		Year ended	
		30 June 2022 (Unaudited)	31 March 2022 (Audited - refer note 3)	30 June 2021 (Unaudited)	31 March 2022 (Audited)
I	Revenue from operations	7,095.42	10,655.30	7,821.15	40,584.24
II	Other income	301.25	516.02	273.89	1,538.25
III	Total income (I + II)	7,396.67	11,171.32	8,095.04	42,122.49
IV	Expenses				
	(a) Cost of materials consumed	2,673.20	3,446.13	2,663.46	12,186.02
	(b) Purchases of stock-in-trade	1,339.60	1,773.50	1,081.01	6,410.22
	(c) Changes in inventories of finished goods and stock-in-trade	(513.93)	(215.03)	(364.17)	(549.99)
	(d) Employee benefits expense	1,210.98	1,230.40	1,225.06	4,822.90
	(e) Advertisement and selling expenditure	989.19	856.31	932.14	5,503.26
	(f) Finance cost	2.44	30.08	8.48	48.45
	(g) Depreciation and amortisation expense	106.70	119.30	92.04	379.52
	(h) Other expenses	1,063.44	1,928.70	828.40	4,264.45
	Total expenses (IV)	6,871.62	9,169.39	6,466.42	33,064.83
V	Profit before tax (III - IV)	525.05	2,001.93	1,628.62	9,057.66
VI	Tax expenses	158.65	531.34	422.88	2,338.77
VII	Profit after tax (V - VI)	366.40	1,470.59	1,205.74	6,718.89
VIII	Other comprehensive income				
	Items that will not be reclassified subsequently to profit or loss				
	Re-measurement gain/(loss) on defined benefit plans, net of taxes	(72.59)	2.72	(2.59)	(63.84)
	Other comprehensive income/ (loss) for the period, net of taxes	(72.59)	2.72	(2.59)	(63.84)
IX	Total comprehensive income for the period (VII + VIII)	293.81	1,473.31	1,203.15	6,655.05
	Paid-up equity share capital (Face value Re. 1/- each)	292.31	292.31	292.31	292.31
	Earnings per share				
	Basic earnings per share (INR)	1.26	5.09	4.12	23.05
	Diluted earnings per share (INR)	1.25	5.08	4.12	23.03
		(not annualised)	(not annualised)	(not annualised)	(annualised)
	<i>See accompanying notes to financial results</i>				




AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

1. The above financial results for the quarter ended 30 June 2022 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12 August 2022. The above results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
2. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The figures for the 3 months ended March 31, 2022 as reported in these financial results are the balancing figures between the audited figures in respect of the full previous financial year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
4. The financial results of the Company for the Quarter ended 30 June 2022 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com.
5. **Segment reporting in the financial results:** Based on the 'management approach' as defined in Ind AS 108 "Operating Segments", the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

		(Rs.in Lakhs)			
Particulars	Quarter ended			Year ended	
	30 June 2022 (Unaudited)	31 March 2022 (Audited - refer note 3)	30 June 2021 (Unaudited)	31 March 2022 (Audited)	
1 Segment revenue					
a OTC Products	6,241.35	9,407.10	6,720.15	37,221.24	
b Beverages	796.40	1,189.38	1,074.24	3,190.46	
c Others	57.67	58.82	26.76	172.54	
Total	7,095.42	10,655.30	7,821.15	40,584.24	
2 Segment results					
a OTC Products	442.23	2,007.32	1,338.35	8,288.14	
b Beverages	(143.46)	(93.19)	85.63	(7.09)	
c Others	(13.46)	(13.85)	(34.78)	(96.57)	
Total	285.31	1,900.28	1,389.20	8,184.48	
Less: Finance cost	(2.44)	(30.08)	(8.48)	(48.45)	
Add: Other unallocable income net of expenses	242.18	131.73	247.90	921.63	
Total profit before tax	525.05	2,001.93	1,628.62	9,057.66	
3 Segment assets					
a OTC Products	8,484.29	9,091.91	5,468.08	9,091.91	
b Beverages	2,408.96	2,073.42	934.40	2,073.42	
c Others	58.90	65.43	89.48	65.43	
d Unallocated assets	24,166.90	23,756.05	22,687.06	23,756.05	
Total	35,119.05	34,986.81	29,179.02	34,986.81	
4 Segment liabilities					
a OTC Products	6,558.88	5,492.11	4,722.58	5,492.11	
b Beverages	849.29	1,812.52	1,035.09	1,812.52	
c Others	60.17	68.28	87.45	68.28	
d Unallocated liabilities	833.87	1,101.52	546.86	1,101.52	
Total	8,302.21	8,474.43	6,391.98	8,474.43	
Total capital employed in the Company	26,816.84	26,512.38	22,787.04	26,512.38	

for Amrutanjan Health Care Limited



S Sambhu Prasad
Chairman and Managing Director
DIN: 00015729

Date: 12 August 2022
Place: Chennai

BSR & Co. LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floors,
No.1, Harrington Road, Chetpet,
Chennai – 600 031, India

Telephone: +91 44 4608 3100
Fax: +91 44 4608 3199

Limited Review Report on unaudited financial results of AMRUTANJAN HEALTH CARE LIMITED for the quarter ended 30 JUNE 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of AMRUTANJAN HEALTH CARE LIMITED

1. We have reviewed the accompanying Statement of unaudited financial results of AMRUTANJAN HEALTH CARE LIMITED ("the Company") for the quarter ended 30 June 2022 ("the Statement") in which are included the interim unaudited financials results of Employee Stock Option Plan ("ESOP Trust").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim unaudited financials results of ESOP Trust, as included in the Statement, whose total assets of INR 451.67 Lakhs, total revenue of INR Nil and total net loss after tax of INR 0.01 Lakhs for the quarter ended 30 June 2022 as considered in the statement.

Registered Office:

B S R & Co. LLP

Our conclusion on the statement is not modified in respect of the above matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248W/W-100022

KASIVswanath
han raghuram

Digitally signed by
KASIVswanathan raghuram
Date: 2022.08.12 17:05:01
+05'30'

K Raghuram

Partner

Chennai

12 August 2022

Membership No.: 211171

UDIN:22211171AOXJIB6175